Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and collection of blood samples; intraosseous access systems consisting of EZ-IO intraosseous vascular access systems, and Arrow FAST1 sternal intraosseous infusion systems; and hemostatic products, including external hemostats and trauma products under the QuikClot brand. It also provides interventional products, including various coronary catheters, structural heart support devices, and peripheral intervention products platforms; GuideLiner, Turnpike, and TrapLiner catheters; MANTA vascular closure devices and Arrow OnControl powered bone biopsy systems; and coronary and peripheral medical devices, such as drug-coated balloons, stents, and balloon catheters. In addition, the company offers surgical products, including metal and polymer ligating clips using manual and automatic applier system, fascial closure surgical systems used in laparoscopic surgical procedures, percutaneous surgical systems, powered bariatric staplers, and other surgical instruments under the Weck, MiniLap, Pleur-Evac, Deknatel, KMedic, Pilling, and Titan SGS brands. It serves hospitals, healthcare providers, and medical device manufacturers. The company also sells its products online. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $2.0B | $303M | $-906M | $245M | -29.0% | 17.2% | -1399.8% |
| 2024 | $1.7B | $271M | $70M | $545M | 1.6% | -0.8% | -80.4% |
| 2023 | $1.7B | $419M | $356M | $464M | 8.0% | -38.6% | -1.9% |
| 2022 | $2.8B | $731M | $363M | $263M | 9.0% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 2,791.04 | 1,712.44 | 1,699.55 | 1,992.71 |
| Operating Revenue | - | 2,791.04 | 1,712.44 | 1,699.55 | 1,992.71 |
| Cost Of Revenue | - | 1,259.95 | 672.33 | 662.16 | 871.96 |
| Gross Profit | - | 1,531.09 | 1,040.11 | 1,037.39 | 1,120.75 |
| Operating Expense | - | 1,017.57 | 736.37 | 783.54 | 864.95 |
| Research And Development | - | 153.82 | 113.63 | 109.02 | 144.78 |
| Selling General And Administration | - | 863.75 | 622.74 | 674.52 | 720.17 |
| Total Expenses | - | 2,277.52 | 1,408.70 | 1,445.70 | 1,736.91 |
| Operating Income | - | 513.52 | 303.74 | 253.85 | 255.80 |
| Total Operating Income As Reported | - | 499.72 | 258.73 | 103.65 | 118.37 |
| EBITDA | - | 730.77 | 418.51 | 271.34 | 302.51 |
| Normalized EBITDA | - | 745.02 | 463.53 | 421.53 | 439.94 |
| EBIT | - | 500.18 | 270.40 | 109.80 | 124.78 |
| Interest Income | - | 0.91 | 11.68 | 6.15 | 6.40 |
| Interest Expense | - | 54.26 | 85.01 | 83.51 | 100.22 |
| Net Interest Income | - | -53.35 | -73.33 | -77.36 | -93.82 |
| Other Income Expense | - | -14.25 | -45.02 | -150.20 | -137.43 |
| Interest Income Non Operating | - | 0.91 | 11.68 | 6.15 | 6.40 |
| Interest Expense Non Operating | - | 54.26 | 85.01 | 83.51 | 100.22 |
| Net Non Operating Interest Income Expense | - | -53.35 | -73.33 | -77.36 | -93.82 |
| Pretax Income | - | 445.92 | 185.39 | 26.29 | 24.55 |
| Tax Provision | - | 83 | 41.87 | -30.90 | -33.98 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -2.65 | -10.17 | -31.54 | -28.86 |
| Net Income Continuous Operations | - | 362.92 | 143.52 | 57.19 | 58.53 |
| Net Income From Continuing And Discontinued Operation | - | 363.14 | 356.33 | 69.68 | -905.64 |
| Net Income From Continuing Operation Net Minority Interest | - | 362.92 | 143.52 | 57.19 | 58.53 |
| Net Income | - | 363.14 | 356.33 | 69.68 | -905.64 |
| Net Income Common Stockholders | - | 363.14 | 356.33 | 69.68 | -905.64 |
| Net Income Including Noncontrolling Interests | - | 363.14 | 356.33 | 69.68 | -905.64 |
| Normalized Income | - | 374.51 | 178.37 | 175.85 | 167.10 |
| Diluted NI Availto Com Stockholders | - | 363.14 | 356.33 | 69.68 | -905.64 |
| Basic Average Shares | - | 46.90 | 46.98 | 46.84 | 44.62 |
| Diluted Average Shares | - | 47.31 | 47.30 | 47.09 | 44.72 |
| Reconciled Depreciation | - | 230.59 | 148.10 | 161.53 | 177.74 |
| Reconciled Cost Of Revenue | - | 1,259.95 | 672.33 | 662.16 | 871.96 |
| Total Unusual Items | - | -14.25 | -45.02 | -150.20 | -137.43 |
| Total Unusual Items Excluding Goodwill | - | -14.25 | -45.02 | -150.20 | -137.43 |
| Net Income Discontinuous Operations | - | 0.22 | 212.81 | 12.48 | -964.17 |
| Special Income Charges | - | -14.25 | -45.02 | -150.20 | -137.43 |
| Gain On Sale Of Business | 91.16 | 6.50 | 4.45 | 0 | - |
| Other Special Charges | 12.99 | 0.45 | 45.24 | 132.73 | - |
| Write Off | - | 1.50 | 0 | 7.83 | 108.12 |
| Impairment Of Capital Assets | - | 0 | 0 | 240 | - |
| Restructuring And Mergern Acquisition | - | 18.80 | 4.22 | 9.63 | 29.31 |
| Gain On Sale Of Ppe | - | - | 4.45 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Teleflex Incorporatedthis co. | TFX | $5.8B | -6.46 | 1.87 | -29.0% | 27.09 |
| Alkermes plc | ALKS | $7.2B | 29.92 | 3.97 | 13.3% | 20.89 |
| Glaukos Corporation | GKOS | $7.1B | -38.08 | 10.89 | -28.6% | -49.02 |
| Protagonist Therapeutics, Inc. | PTGX | $6.6B | -50.79 | 10.75 | -21.2% | -41.39 |
| TG Therapeutics, Inc. | TGTX | $6.2B | 13.88 |
| - |
| - |
| - |
| - |
| - |
| 9.58 |
| 69.0% |
| 47.51 |
| PTC Therapeutics, Inc. | PTCT | $5.9B | 8.58 | - | -332.5% | 7.46 |
| Apellis Pharmaceuticals, Inc. | APLS | $5.3B | 234.62 | 14.19 | 6.0% | 75.16 |
| Ligand Pharmaceuticals Incorporated | LGND | $4.7B | 37.99 | 4.65 | 12.2% | 25.35 |
| Indivior Pharmaceuticals, Inc. | INDV | $4.4B | 21.08 | -44.71 | -212.1% | 15.07 |
| Peer Median | - | 17.48 | 9.58 | -7.6% | 17.98 | |